186 related articles for article (PubMed ID: 36271188)
1. Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study.
Li B; Li G; Song Z; Zhang Z
Rheumatol Ther; 2023 Feb; 10(1):149-160. PubMed ID: 36271188
[TBL] [Abstract][Full Text] [Related]
2. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
3. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
4. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
[TBL] [Abstract][Full Text] [Related]
5. NETosis in Psoriatic Arthritis: Serum MPO-DNA Complex Level Correlates With Its Disease Activity.
Li B; Li G; Yang X; Song Z; Wang Y; Zhang Z
Front Immunol; 2022; 13():911347. PubMed ID: 35774788
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
[TBL] [Abstract][Full Text] [Related]
7. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
Lubrano E; Scriffignano S; Perrotta FM
J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
[TBL] [Abstract][Full Text] [Related]
8. Differences in oxylipin profile in psoriasis versus psoriatic arthritis.
Coras R; Kavanaugh A; Kluzniak A; Holt D; Weilgosz A; Aaron A; Quehenberger O; Ritchlin C; Guma M
Arthritis Res Ther; 2021 Jul; 23(1):200. PubMed ID: 34303373
[TBL] [Abstract][Full Text] [Related]
9. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
10. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.
Jarlborg M; Courvoisier DS; Lamacchia C; Martinez Prat L; Mahler M; Bentow C; Finckh A; Gabay C; Nissen MJ;
Arthritis Res Ther; 2020 May; 22(1):105. PubMed ID: 32375861
[TBL] [Abstract][Full Text] [Related]
11. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
12. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
[TBL] [Abstract][Full Text] [Related]
13. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease.
Coates LC; FitzGerald O; Gladman DD; McHugh N; Mease P; Strand V; Helliwell PS
Arthritis Rheum; 2013 Jun; 65(6):1504-9. PubMed ID: 23529837
[TBL] [Abstract][Full Text] [Related]
14. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.
Rahman P; Zummer M; Bessette L; Baer P; Haraoui B; Chow A; Kelsall J; Kapur S; Rampakakis E; Psaradellis E; Lehman AJ; Nantel F; Osborne B; Tkaczyk C
BMJ Open; 2017 Aug; 7(8):e016619. PubMed ID: 28855200
[TBL] [Abstract][Full Text] [Related]
15. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
[TBL] [Abstract][Full Text] [Related]
16. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
[TBL] [Abstract][Full Text] [Related]
17. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.
Michelsen B; Diamantopoulos AP; Hammer HB; Soldal DM; Kavanaugh A; Haugeberg G
Ann Rheum Dis; 2016 Dec; 75(12):2108-2113. PubMed ID: 27091837
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
19. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
[TBL] [Abstract][Full Text] [Related]
20. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease.
Eissa A; Cretu D; Soosaipillai A; Thavaneswaran A; Pellett F; Diamandis A; Cevikbas F; Steinhoff M; Diamandis EP; Gladman D; Chandran V
Clin Chem Lab Med; 2013 Feb; 51(2):317-25. PubMed ID: 23096109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
